Studies on Antibodies and Lasting Immunity

I just found this article. It has multiple links so I hope they come through since I have to copy/paste. Read this about the vaccine!!! Two new important studies which shed new light on everything

A new study from China showed that antibodies faded quickly in both asymptomatic and symptomatic COVID-19 patients during convalescence – raising questions about whether the illness leads to any lasting immunity to the virus afterward.

The study – which focused on 37 asymptomatic and 37 symptomatic patients – showed that more than 90% of both groups showed steep declines in levels of SARS-COV-2–specific immunoglobulin G (IgG) antibodies within 2 to 3 months after onset of infection – according to a report published yesterday in Nature Medicine. Further – 40% of the asymptomatic group tested negative for IgG antibodies 8 weeks after they were released from isolation.

A large study from Spain showed that antibodies can disappear weeks after people have tested positive – causing some to question how possible it will be to attain herd immunity.

A study published in medical journal Lancet showed 14% of people who tested positive for antibodies no longer had antibodies weeks later.

Such findings have implications for vaccine development – since the efficacy of a vaccine hinges on the idea that a dose of weakened or dead virus can prompt your body to generate antibodies that protect you from future infection. If those antibodies are fleeting – a vaccine’s protection would be fleeting too.

Short-lived antibodies also diminish hopes of achieving widespread or permanent herd immunity.

“If antibodies can fade in some patients within weeks – and if just about everyone loses them after a few months – that would render any vaccine almost completely useless.

And if these findings are confirmed – we can pretty much forget about ever achieving “herd immunity”.”

For the first time – in a new study, Azithromycin has been administered alone for mild/moderate Covid-19 patients:

There were 34 subjects treated with AZM alone and 20 with AZM+HCQ. Due to lack of AZM – availability in pharmacies – clarithromycin was prescribed to two patients. NST group included 11 patients without any treatment and 23 who received symptomatic treatment (paracetamol for 20 of them).

The treatments started early after the onset of symptoms – the day of onset for 36 patients (41%) and within 15 days for the others – except for one patient which started treatment at day 40 in the AZM group.

The study – which does not control for Zinc – finds that AZM and AZM+HCQ clearly favourably impacted the resolution time of the symptoms.

“We are potentially facing a future in which COVID-19 will be with us permanently – and people will need to understand that there is a possibility that they will be able to get infected repeatedly.

Sadly – there is evidence that this is already starting to happen for some patients. In a recent article for Vox – a doctor in Washington D.C. named D. Clay Ackerly shared that one of his patients got infected with COVID-19 again three months after being infected the first time.”

And in that same article – Dr. Ackerly explained that other doctors are starting to see similar cases:

Recent reports and conversations with physician colleagues suggest my patient is not alone. Two patients in New Jersey – for instance – appear to have contracted Covid-19 a second time almost two months after fully recovering from their first infection. Daniel Griffin – a physician and researcher at Columbia in New York – recently described a case of presumed reinfection on the This Week in Virology podcast.